30 closest matches · ranked by relevance
Epilepsy · Generalized Tonic-Clonic Seizures
Primary: Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation…
Generalized Tonic Clonic Seizures
Primary: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase — 1.17; 1.13; 1.14 Seizure…
Seizure Disorder Generalized Tonic Clonic
Primary: Median Percent Change in Primary Generalized Tonic Clonic Seizure Frequency (PGTC) Per 28 Days During the Titration and Maintenance Periods (Combined) Relative to…
Epilepsy, Tonic-Clonic
Primary: Percent Change From Baseline in Weekly Primary Generalized Tonic-clonic (PGTC) Seizure Frequency During the Entire Double-Blind Treatment Phase — 32.1; 75.4 percent…
Epilepsy, Idiopathic Generalized
Primary: Time to First Seizure — 169; 178 Days
Epilepsy · Generalized Tonic-clonic Seizures
Primary: The Percent Change From the Combined Baseline (4-week Retrospective Baseline and 4-week Prospective Baseline) in the Generalized Tonic-clonic Seizure Frequency Per Week…
Epilepsy
Primary: Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period — 222 Participants
Epilepsy
Primary: Change in the Number of Seizure Days With Absence Seizures From the Baseline Phase to the Maintenance Phase — -0.37 number of seizure days
Epilepsy · Generalized Tonic-clonic Seizures
Primary: Incidence of Treatment Emergent Adverse Events During the Entire Study Period — 626 Treatment Emergent Adverse Events
Epilepsy, Partial Seizures · Epilepsy, Primary Generalized Tonic-Clonic Seizures
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Related AEs and Treatment Related SAEs…
Tuberous Sclerosis
Primary: Percent Change From Baseline in 28-day Seizure Frequency Through the End of 12-Week Treatment Period — -16.61 Percent change
Epilepsy
Primary: Time to the Second Primary Generalized Tonic Clonic (PGTC) Seizure During the 24-week Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24) — 76; 49 events…
Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) for Total Group of Participants - Core Phase…
Partial Epilepsy · Catamenial Epilepsy
Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]
Epilepsy
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) From Visit 1 to the End of Study (Approximately 61 Weeks) — 37 participants
Tuberous Sclerosis Complex
Primary: Cognitive Assessment Scores and Developmental Impact — 83.9; 80.9; 97.3; 85.0 score on a scale — p=0.8681
Status Epilepticus
Primary: Number of Subjects With Termination of Seizures at ED Arrival With no Rescue Therapy Given — 329; 282 participants — p=<0.001
Partial Onset Seizures · Secondarily Generalized Seizures · Primary Generalized Tonic-Clonic Seizures
Primary: Percentage of Participants Remaining on Perampanel Treatment at 3 Months After the Initiation of Treatment — 85.2 percentage of participants
Status Epilepticus
Primary: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE — 79.59…
Epilepsy
Primary: Mean AUC0-last_ss (Test vs. Reference) — 92.884; 62.76666667; 419.97; 260.3 micro/mL/hr
Lennox-Gastaut Syndrome
Primary: Number of Seizure After Treatment by tDCS — 80.67; 93.43; 35.53; 93.14 seizures — p=<0.05
Epilepsy
Primary: Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment — -28.8; .54 IEDs/hour — p=>0.05
Epilepsy With Partial On-set Seizures
Primary: The Number of Subjects Completing 24 Weeks Adjunctive Therapy During Maintenance Phase — 36; 37 participants
Elderly · Epilepsy · Seizures
Primary: Effectiveness of Medication as Measured by Participation Through the End of the Trial. — 14 participants
Epilepsy
Primary: Number of Subjects in the Safety Analysis Set With at Least 1 Treatment-emergent Adverse Event (TEAE) — 84; 14; 10; 1 Participants
Childhood Absence Epilepsy · Petit Mal Epilepsy · Epilepsy
Primary: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy — 81; 43; 85 Participants — p=<0.001
Tuberous Sclerosis Complex · Seizures
Primary: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) — -43.36…
Epilepsy
Primary: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) — 7 Participants
Tuberous Sclerosis Complex
Primary: Percent Change From Baseline in 28-day Seizure Frequency for Primary Seizure Type During Double Blind Period — -7.50; 13.57 Percent change — p=0.0904
Benign Epilepsy With Centrotemporal Spikes · Language Problems · Learning Disorders
Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04